Company type | Subsidiary |
---|---|
Nasdaq: DNA | |
Industry | Biotechnology |
Founded | 1976 |
Headquarters | South San Francisco, California, United States |
Key people |
|
Products | Avastin, Herceptin, Rituxan, Perjeta, Kadcyla, Gazyva, Tarceva, Ocrevus, Polivy, Tecentriq, Xofluza, Hemlibra, Venclexta, Esbriet, Cotellic, Alecensa, Zelboraf, Nutropin, Actemra, Lucentis, Xolair, Activase, Cathflo Activase, Xeloda, Boniva, TNKase, CellCept, Pegasys, Pulmozyme, Tamiflu, Valcyte, Anaprox, Cytovene, EC-Naprosyn, Erivedge, Fuzeon, Invirase, Klonopin, Kytril, Naprosyn, Rocephin, Roferon-A, Romazicon, Valium, Xenical, Zenapax |
Revenue | $26.4 billion (2020)[4] |
Number of employees | 13,539 (July 2021) |
Parent | Roche |
Website | gene |
Footnotes / references [5] |
Genentech, Inc. is an American biotechnology corporation headquartered in South San Francisco, California. It became an independent subsidiary of Roche in 2009. Genentech Research and Early Development operates as an independent center within Roche.[6] Historically, the company is regarded as the world's first biotechnology company.[7]
As of July 2021, Genentech employed 13,539 people.[8]
fiercebiotech
was invoked but never defined (see the help page).Press_Regev
was invoked but never defined (see the help page).